ArticleHereditary cancer in clinical practice2021

Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin.

Tatiana V Gorodnova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.